Proteomics International Laboratories Overview
- Year Founded
-
2001
- Status
-
Public
- Stock Symbol
-
PIQ
- Investments
-
1
- Share Price
-
$0.06
- (As of Thursday Closing)
Proteomics International Laboratories General Information
Description
Proteomics International Laboratories Ltd is a medical technology company specializing in proteomics and precision diagnostics. The company develops and commercializes blood-based tests designed to support earlier and more precise diagnosis and risk assessment. It has established accredited laboratory facilities in Australia and the United States and is headquartered in Perth, Western Australia. Its products portfolio Promarker D, Promarker Eso, Promarker Endo, and OxiDx. It operates in single segment.
Contact Information
Website
www.proteomics.com.auCorporate Office
- Level 1, 6 Verdun Street
- Nedlands
- Perth, Western Australia 6009
- Australia
Corporate Office
- Level 1, 6 Verdun Street
- Nedlands
- Perth, Western Australia 6009
- Australia
Proteomics International Laboratories Stock Performance
As of 19-Nov-2026, Proteomics International Laboratories’s stock price is $0.06. Its current market cap is $10.5M with 165M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.06 | $0.06 | $0.06 - $0.58 | $10.5M | 165M | 120K |
Proteomics International Laboratories Financials Summary
As of 30-Sep-2026, Proteomics International Laboratories has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 13,210 | 7,942 | 31,279 | 73,247 |
| Revenue | 188 | 621 | 585 | |
| EBITDA | (5,422) | (4,974) | (3,941) | |
| Net Income | (5,799) | (5,250) | (4,179) | |
| Total Assets | 6,113 | 9,655 | 7,269 | |
| Total Debt | 228 | 181 | 211 |
Proteomics International Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Proteomics International Laboratories Comparisons
Industry
Financing
Details
Proteomics International Laboratories Competitors (1)
One of Proteomics International Laboratories’s competitors is Evestra, a Venture Capital-Backed company based in Schertz, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evestra | Venture Capital-Backed | Schertz, TX |
Proteomics International Laboratories Patents
Proteomics International Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024900353-A0 | Airway disease biomarkers | Pending | 14-Feb-2024 | ||
| AU-2023900328-A0 | Airway disease biomarkers | Pending | 10-Feb-2023 | ||
| AU-2022900265-A0 | Airway disease biomarkers | Pending | 09-Feb-2022 | ||
| AU-2020900805-A0 | Endometriosis biomarkers | Pending | 16-Mar-2020 | ||
| AU-2021237128-A1 | Endometriosis biomarkers | Active | 16-Mar-2020 | G01N33/689 |
Proteomics International Laboratories Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Proteomics International Laboratories Investments (1)
Proteomics International Laboratories’s most recent deal was a Secondary Transaction - Private with Agilex Biolabs for . The deal was made on 05-Mar-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Agilex Biolabs | 05-Mar-2018 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology |
Proteomics International Laboratories ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Proteomics International Laboratories Exits (1)
Proteomics International Laboratories’s most recent exit was on 05-Mar-2018 from Agilex Biolabs. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Agilex Biolabs | 05-Mar-2018 | Completed |
|
Proteomics International Laboratories FAQs
-
When was Proteomics International Laboratories founded?
Proteomics International Laboratories was founded in 2001.
-
Where is Proteomics International Laboratories headquartered?
Proteomics International Laboratories is headquartered in Perth, Australia.
-
What industry is Proteomics International Laboratories in?
Proteomics International Laboratories’s primary industry is Diagnostic Equipment.
-
Is Proteomics International Laboratories a private or public company?
Proteomics International Laboratories is a Public company.
-
What is Proteomics International Laboratories’s stock symbol?
The ticker symbol for Proteomics International Laboratories is PIQ.
-
What is the current stock price of Proteomics International Laboratories?
As of 19-Nov-2026 the stock price of Proteomics International Laboratories is $0.06.
-
What is the current market cap of Proteomics International Laboratories?
The current market capitalization of Proteomics International Laboratories is $10.5M.
-
Who are Proteomics International Laboratories’s competitors?
Evestra is a competitor of Proteomics International Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process